ClinicalTrials.gg
RecruitingNCT07300566FORWARDUpdated Oct 5, 2026

Focal Versus Whole Gland High Dose-Rate Brachytherapy (HDR-BT) Boost to External Beam Radiotherapy in Localized Prostate Cancer: A Phase 2 Randomized Trial

An interventional study of Standard Arm: Whole Gland High Dose Rate Brachytherapy Boost and Experimental Arm: Focal High Dose Rate Brachytherapy Boost in Prostate Cancer, sponsored by Joelle Helou. Recruiting at 1 site in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Joelle Helou · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 5, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 713 studies in Prostatic Neoplasms with a site in Canada — 119 open to participants now, 223 under way, 64 of them phase 3. Prostatic Neoplasms · Canada.

Planned enrollment
408th of 636
58 · median 100
Started
2026
with 28 others
No phase
190 of 713
47 open now
Primary completion
2031-03
later than 202 of 222 live
Registered
689th of 713
by date

Among the 713 studies in Prostatic Neoplasms with a site in Canada, this one is the 408th largest by planned enrollment of the 636 interventional ones that give a count, is one of 29 that started in 2026, is one of 190 with no phase, reaches primary completion later than 202 of the 222 other live ones, and was the 689th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

119 of the 713 studies in Prostatic Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

113 more — sign in →

All 119 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 713 studies in Prostatic Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

This project aims to compare the changes in the urinary quality of life (QoL) following focal high dose-rate brachytherapy (HDR-BT) boost to stereotactic ablative radiotherapy (SABR), compared to standard whole gland HDR-BT boost, in the treatment of men diagnosed with intermediate- and high-risk prostate cancer, with have an identifiable DIL on mpMRI.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Focal high dose rate brachytherapy
  • Whole gland high dose rate brachytherapy
  • External beam radiotherapy
  • Intermediate risk prostate cancer
  • High risk prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of adenocarcinoma of the prostate
  • Eastern Co-Operative Oncology Group () 0-2
  • Intermediate and high-risk disease with localized unfavorable features:

    • defined as clinical stage tumor cT1 or cT2a, International Society of Urological Pathology (ISUP) grade group 2-4 in less than or equal to 50% of the cores, unilateral extracapsular extension (ECE), prostate specific antigen (PSA) less than or equal to 20 ng/mL
    • corresponding to an Identified dominant intraprostatic lesion (DIL) on multiparametric magnetic resonance imaging (mpMRI) Prostate Imaging Reporting and Data System score (PI-RADs 3-5)
  • Prostate volume less than or equal to 60 cc is recommended. Transrectal ultrasound (TRUS) and magnetic resonance imaging (MRI) are accepted to assess prostate volume. Patients with a prostate volume between 60 and 80 cc can be included if the International Prostate Symptom Score (IPSS) is less than 15 and brachytherapy is deemed feasible by the treating physician.

Exclusion criteria

Exclusion Criteria:

  • to mpMRI
  • Documented nodal or distant
  • Previous pelvic radiotherapy
  • Recent transurethral resection of prostate (less than or equal to 6 months), previous prostatectomy or high-intensity focused ultrasound (HIFU)
  • Poor baseline urinary function: International Prostate Symptom Score (IPSS) greater than 19
  • Connective tissue disease or inflammatory bowel disease
  • Patients deemed unsuitable for general anaesthetic by the Anaesthesia Department
  • Patient is unable to lie flat long enough for the Radiation Therapy (RT) Simulation and Treatment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • Active comparator
    Whole Gland High Dose Rate Brachytherapy Boost Arm

    Radiation: Standard Arm: Whole Gland High Dose Rate Brachytherapy Boost

  • Experimental
    Focal High Dose Rate Brachytherapy Boost Arm

    Radiation: Experimental Arm: Focal High Dose Rate Brachytherapy Boost

Interventions

  • RadiationStandard Arm: Whole Gland High Dose Rate Brachytherapy Boost

    Whole gland high dose rate brachytherapy (15 Gray/1 fraction) plus stereotactic ablative radiotherapy to the prostate +/- pelvis (25 Gray/5 fractions). Androgen deprivation therapy 6 to 24 months (physician discretion).

  • RadiationExperimental Arm: Focal High Dose Rate Brachytherapy Boost

    Focal high dose rate brachytherapy boost to the dominant intraprostatic lesion (15 Gray/1 fraction) plus stereotactic ablative radiotherapy to the prostate (30 Gray/5 fractions) +/- the pelvis (25 Gray/5 fractions). Androgen deprivation therapy 6 to 24 months (physician discretion).

06

What researchers measure

Primary outcomes

  1. Changes in Urinary Quality of Life at 24 Months Measured by the Expanded Prostate Index Composite (EPIC-26) Questionnaire

    To compare the impact on urinary quality of life (QoL) between focal high dose-rate brachytherapy (HDR-BT) boost and standard whole gland HDR-BT boost to stereotactic ablative radiotherapy (SABR) as reported by the participant on the Expanded Prostate Index Composite (EPIC-26) questionnaire.

    Time frame: From enrollment to 24 months post radiation therapy

Secondary outcomes

  1. Acute Changes in Urinary, Bowel, and Sexual Quality of Life

    Time frame: Less than or equal to 6 months post radiation therapy

  2. Long Term Changes in Bowel and Sexual Quality of Life Measured by Expanded Prostate Index Composite (EPIC-26) Questionnaire

    Changes in bowel and sexual health as reported by the participant on the Expanded Prostate Index Composite (EPIC-26) questionnaire.

    Time frame: From enrollment to 24 months post radiation therapy

  3. Acute and Chronic Physician-Reported Toxicity Using Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

    Severity and grade of side effects of treatment as reported by the physician using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: From enrollment to 24 months post radiation therapy

  4. Prostate Specific Antigen (PSA) at 4 years

    Blood test measuring the amount of PSA protein made by the prostate.

    Time frame: 4 years post radiation therapy

  5. Biochemical Control Measure by Prostate Specific Antigen (PSA) Levels

    Time frame: Enrollment to 5 years post radiation therapy

  6. Participant reported Symptoms Measured by the Patient Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    Frequency and severity of side effects of treatment as reported by the participant on the Patient Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) questionnaire.

    Time frame: From enrollment to 24 months post radiation therapy

07

Study locations

1 of 1 sites recruiting
  • London Health Sciences Centre, Verspeeten Family Cancer Centre
    London, Ontario N6A 5W9, Canada
    Recruiting
    • Joelle Helou, MD · ContactJoelle.Helou@lhsc.on.ca · 519-685-8650
    • Joelle Helou, MD · Principal investigator
    • Lucas Mendez, MD · Sub investigator
    • David D'Souza, MD · Sub investigator
    • Rohann Correa, MD · Sub investigator
    • Belal Ahmad, MD · Sub investigator
    • Glenn Bauman, MD · Sub investigator
    • Michael Lock, MD · Sub investigator
    • George Rodrigues, MD · Sub investigator
    • Vikram Velker, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Mar 2031, 57 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 57 months is above that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Jun 2026, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Dec 24, 2025
StartActual
Jun 10, 2026was Feb 2026
Primary completionEst.
Mar 2031
CompletionEst.
Mar 2033
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 5, 2026
Sites
London Health Sciences Centre, Verspeeten Family Cancer Centre is now Recruiting
Oct 5, 2026
Start date
Feb 2026→Jun 10, 2026 (actual)
Oct 5, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • London Health Sciences Centre, Verspeeten Family Cancer Centre · London, CanadaContact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)
Oct 5, 2026
Design
Phase 2→Not applicable
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Not yet recruiting→Recruiting
    London Health Sciences Centre, Verspeeten Family Cancer Centre is now Recruiting
    Start date Feb 2026→Jun 10, 2026 (now actual)
    Design Phase 2→Not applicable
    Site contacts Changed at 1 site. See the sites
    Show the site
    • London Health Sciences Centre, Verspeeten Family Cancer Centre · London, CanadaContact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07300566
Lead sponsor
Joelle Helou
Collaborators
London Health Sciences Centre
Responsible party
Joelle Helou (Principal Investigator, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's) — Sponsor-investigator
First posted
Dec 24, 2025
Start date
Jun 10, 2026
Primary completion
Mar 2031 (estimated)
Completion
Mar 2033 (estimated)
Last update
Oct 5, 2026

Study contacts

Joelle Helou, MD
Contact
Joelle.Helou@lhsc.on.ca
519-685-8650
Joelle Helou, MD
principal investigator · London Health Sciences Centre Research Institute, London Health Sciences Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion